This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
-
Working with individual set: LAML-TB
-
Number of patients in set: 197
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:LAML-TB.final_analysis_set.maf
-
Significantly mutated genes (q ≤ 0.1): 24
-
Mutations seen in COSMIC: 238
-
Significantly mutated genes in COSMIC territory: 19
-
Genes with clustered mutations (≤ 3 aa apart): 18
-
Significantly mutated genesets: 69
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 197 MAFs of type "WashU"
-
Total number of mutations in input MAFs: 2585
-
After removing 41 mutations outside chr1-24: 2544
-
After removing 1 blacklisted mutations: 2543
-
After removing 104 noncoding mutations: 2439
-
Number of mutations before filtering: 2439
-
After removing 204 mutations outside gene set: 2235
-
After removing 14 mutations outside category set: 2221
type | count |
---|---|
Frame_Shift_Del | 51 |
Frame_Shift_Ins | 110 |
In_Frame_Del | 8 |
In_Frame_Ins | 43 |
Missense_Mutation | 1401 |
Nonsense_Mutation | 108 |
Silent | 450 |
Splice_Site | 50 |
Total | 2221 |
category | n | N | rate | rate_per_mb | relative_rate |
---|---|---|---|---|---|
*CpG->T | 509 | 272310736 | 1.9e-06 | 1.9 | 5.8 |
*Cp(A/C/T)->T | 312 | 2468091057 | 1.3e-07 | 0.13 | 0.39 |
A->G | 182 | 2745259222 | 6.6e-08 | 0.066 | 0.21 |
transver | 398 | 5485661015 | 7.3e-08 | 0.073 | 0.22 |
indel+null | 357 | 5485661212 | 6.5e-08 | 0.065 | 0.2 |
double_null | 13 | 5485661212 | 2.4e-09 | 0.0024 | 0.0073 |
Total | 1771 | 5485661212 | 3.2e-07 | 0.32 | 1 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->T
-
n3 = number of nonsilent mutations of type: A->G
-
n4 = number of nonsilent mutations of type: transver
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_cons | p_joint | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 115442 | 15 | 15 | 6 | 0 | 0 | 8 | 1 | 6 | 0 | 0 | 1.09e-14 | 0.28 | 4.2e-06 | 0.000 | 0.000 |
2 | WT1 | Wilms tumor 1 | 164692 | 12 | 12 | 10 | 0 | 1 | 1 | 0 | 0 | 9 | 1 | 6.00e-15 | 1 | 0.00022 | 0.000 | 0.000 |
3 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 145189 | 20 | 18 | 16 | 0 | 2 | 3 | 2 | 2 | 10 | 1 | <1.00e-15 | 0.016 | 0.0031 | <1.11e-16 | <6.39e-13 |
4 | FLT3 | fms-related tyrosine kinase 3 | 597107 | 56 | 56 | 30 | 0 | 0 | 0 | 1 | 16 | 39 | 0 | 6.55e-15 | 4.2e-06 | 0 | <1.00e-15 | <1.92e-12 |
5 | NPM1 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) | 183407 | 54 | 54 | 7 | 0 | 0 | 0 | 1 | 0 | 52 | 1 | <1.00e-15 | 0 | 0 | <1.00e-15 | <1.92e-12 |
6 | DNMT3A | DNA (cytosine-5-)-methyltransferase 3 alpha | 512791 | 57 | 51 | 29 | 0 | 34 | 2 | 3 | 4 | 14 | 0 | 1.11e-15 | 0 | 0 | <1.00e-15 | <1.92e-12 |
7 | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial | 230293 | 20 | 20 | 2 | 0 | 16 | 3 | 0 | 1 | 0 | 0 | 3.89e-15 | 0.74 | 0 | <1.00e-15 | <1.92e-12 |
8 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 251569 | 19 | 19 | 2 | 0 | 17 | 0 | 0 | 2 | 0 | 0 | <1.00e-15 | 0.98 | 0 | <1.00e-15 | <1.92e-12 |
9 | U2AF1 | U2 small nuclear RNA auxiliary factor 1 | 153266 | 8 | 8 | 2 | 0 | 0 | 5 | 0 | 3 | 0 | 0 | 1.45e-14 | 0.00038 | 0 | <1.00e-15 | <1.92e-12 |
10 | TP53 | tumor protein p53 | 258267 | 18 | 15 | 18 | 1 | 3 | 2 | 3 | 2 | 8 | 0 | <1.00e-15 | 0.32 | 0.04 | <1.55e-15 | <2.68e-12 |
11 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 139279 | 8 | 8 | 6 | 0 | 0 | 4 | 1 | 3 | 0 | 0 | 2.28e-14 | 0.65 | 0.039 | 3.14e-14 | 4.93e-11 |
12 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) | 359328 | 9 | 9 | 9 | 0 | 0 | 3 | 2 | 4 | 0 | 0 | 1.32e-14 | 0.3 | 0.085 | 3.96e-14 | 5.70e-11 |
13 | TET2 | tet oncogene family member 2 | 689894 | 21 | 17 | 20 | 0 | 0 | 2 | 0 | 2 | 11 | 6 | 6.55e-15 | 0.18 | 0.4 | 9.14e-14 | 1.21e-10 |
14 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 585287 | 9 | 8 | 5 | 0 | 1 | 0 | 0 | 6 | 1 | 1 | 1.02e-11 | 0.1 | 0.017 | 5.25e-12 | 6.47e-09 |
15 | PHF6 | PHD finger protein 6 | 244083 | 6 | 6 | 6 | 0 | 0 | 1 | 0 | 1 | 4 | 0 | 4.17e-11 | 0.088 | 0.18 | 2.06e-10 | 2.37e-07 |
16 | SMC1A | structural maintenance of chromosomes 1A | 744857 | 7 | 7 | 7 | 0 | 3 | 0 | 1 | 2 | 1 | 0 | 4.85e-09 | 0.041 | 0.14 | 1.55e-08 | 1.68e-05 |
17 | SMC3 | structural maintenance of chromosomes 3 | 738947 | 7 | 7 | 7 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1.54e-09 | 0.2 | 0.51 | 1.72e-08 | 1.75e-05 |
18 | RAD21 | RAD21 homolog (S. pombe) | 383756 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 6.34e-08 | 0.71 | 0.34 | 4.02e-07 | 0.000386 |
19 | STAG2 | stromal antigen 2 | 775983 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 8.03e-08 | 0.94 | 0.39 | 5.75e-07 | 0.000523 |
20 | FAM5C | family with sequence similarity 5, member C | 458813 | 6 | 5 | 6 | 0 | 4 | 1 | 0 | 1 | 0 | 0 | 2.23e-07 | 0.61 | 1 | 3.64e-06 | 0.00314 |
21 | EZH2 | enhancer of zeste homolog 2 (Drosophila) | 459010 | 3 | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0.000113 | 0.83 | 0.026 | 4.09e-05 | 0.0337 |
22 | ASXL1 | additional sex combs like 1 (Drosophila) | 903245 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 1.14e-05 | 0.86 | 0.47 | 7.04e-05 | 0.0553 |
23 | CBFB | core-binding factor, beta subunit | 87862 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 8.73e-06 | 0.38 | 0.78 | 8.75e-05 | 0.0657 |
24 | BAGE4 | B melanoma antigen family, member 4 | 24822 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.000133 | NaN | NaN | 0.000133 | 0.0958 |
25 | PHACTR1 | phosphatase and actin regulator 1 | 323868 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0.000111 | 0.72 | 0.12 | 0.000164 | 0.113 |
26 | GATA2 | GATA binding protein 2 | 159964 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.000467 | 0.026 | 0.036 | 0.000201 | 0.134 |
27 | DIS3 | DIS3 mitotic control homolog (S. cerevisiae) | 537613 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.000104 | 0.33 | 0.18 | 0.000224 | 0.143 |
28 | CLEC18B | C-type lectin domain family 18, member B | 209805 | 2 | 2 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0.000231 | NaN | NaN | 0.000231 | 0.143 |
29 | SUZ12 | suppressor of zeste 12 homolog (Drosophila) | 395182 | 3 | 3 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 8.84e-05 | 0.8 | 0.36 | 0.000361 | 0.215 |
30 | PKIB | protein kinase (cAMP-dependent, catalytic) inhibitor beta | 48265 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.000425 | NaN | NaN | 0.000425 | 0.245 |
31 | NR2E1 | nuclear receptor subfamily 2, group E, member 1 | 182225 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.000527 | 0.092 | 0.1 | 0.000582 | 0.314 |
32 | LYRM5 | LYR motif containing 5 | 55357 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0.000583 | NaN | NaN | 0.000583 | 0.314 |
33 | HNRNPK | heterogeneous nuclear ribonucleoprotein K | 293530 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.000610 | 0.8 | 0.11 | 0.000685 | 0.359 |
34 | GSTK1 | glutathione S-transferase kappa 1 | 172769 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0.00153 | 0.23 | 0.046 | 0.000741 | 0.377 |
35 | KCNE3 | potassium voltage-gated channel, Isk-related family, member 3 | 62252 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0.000781 | NaN | NaN | 0.000781 | 0.386 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | TP53 | tumor protein p53 | 18 | 824 | 16 | 162328 | 3427 | 0 | 0 |
2 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 19 | 5 | 19 | 985 | 28348 | 5.2e-14 | 9.1e-11 |
3 | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial | 20 | 6 | 20 | 1182 | 2000 | 6.3e-14 | 9.1e-11 |
4 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) | 9 | 32 | 8 | 6304 | 216 | 3.3e-13 | 3e-10 |
5 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 15 | 33 | 15 | 6501 | 11840 | 3.4e-13 | 3e-10 |
6 | NPM1 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) | 54 | 41 | 53 | 8077 | 112668 | 4.3e-13 | 3.1e-10 |
7 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 8 | 52 | 7 | 10244 | 46308 | 5.4e-13 | 3.4e-10 |
8 | FLT3 | fms-related tyrosine kinase 3 | 56 | 124 | 52 | 24428 | 6301 | 1.3e-12 | 7e-10 |
9 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 20 | 178 | 18 | 35066 | 93 | 1.8e-12 | 8.3e-10 |
10 | WT1 | Wilms tumor 1 | 12 | 185 | 9 | 36445 | 444 | 1.9e-12 | 8.3e-10 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12 |
---|---|---|---|---|---|---|---|---|---|---|
337 | DNMT3A | DNA (cytosine-5-)-methyltransferase 3 alpha | 57 | 0 | 408 | 410 | 427 | 408 | 410 | 427 |
535 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 19 | 0 | 171 | 171 | 171 | 171 | 171 | 171 |
536 | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial | 20 | 0 | 139 | 139 | 139 | 139 | 139 | 139 |
429 | FLT3 | fms-related tyrosine kinase 3 | 55 | 0 | 120 | 120 | 136 | 120 | 120 | 136 |
752 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 15 | 0 | 31 | 51 | 51 | 31 | 51 | 51 |
955 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 20 | 0 | 16 | 21 | 26 | 16 | 21 | 26 |
589 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 9 | 0 | 10 | 10 | 10 | 10 | 10 | 10 |
598 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 8 | 0 | 3 | 7 | 7 | 3 | 7 | 7 |
902 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) | 9 | 0 | 1 | 3 | 10 | 1 | 3 | 10 |
1109 | TET2 | tet oncogene family member 2 | 21 | 0 | 1 | 1 | 2 | 1 | 1 | 2 |
Note:
n - number of mutations in this gene in the individual set.
mindist - distance (in aa) between closest pair of mutations in this gene
npairs3 - how many pairs of mutations are within 3 aa of each other.
npairs12 - how many pairs of mutations are within 12 aa of each other.
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | HSA00480_GLUTATHIONE_METABOLISM | Genes involved in glutathione metabolism | ANPEP, G6PD, GCLC, GCLM, GGT1, GGTL3, GGTL4, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, OPLAH, TXNDC12 | 34 | GCLM(1), GPX2(1), GSTK1(2), GSTM3(1), IDH1(19), IDH2(20) | 5770918 | 44 | 42 | 9 | 0 | 34 | 4 | 0 | 6 | 0 | 0 | <1.00e-15 | <2.05e-13 |
2 | GLUTATHIONE_METABOLISM | ANPEP, G6PD, GCLC, GCLM, GGT1, GPX1, GPX2, GPX3, GPX4, GPX5, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, PGD | 29 | GCLM(1), GPX2(1), GSTM3(1), IDH1(19), IDH2(20) | 5170462 | 42 | 40 | 7 | 0 | 33 | 4 | 0 | 5 | 0 | 0 | <1.00e-15 | <2.05e-13 | |
3 | HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | Genes involved in cytokine-cytokine receptor interaction | ACVR1, ACVR1B, ACVR2A, ACVR2B, AMH, AMHR2, BMP2, BMP7, BMPR1A, BMPR1B, BMPR2, CCL1, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL7, CCL8, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD27, CD40, CD40LG, CD70, CLCF1, CNTF, CNTFR, CRLF2, CSF1, CSF1R, CSF2, CSF2RA, CSF2RB, CSF3, CSF3R, CTF1, CX3CL1, CX3CR1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, CXCR3, CXCR4, CXCR6, EDA, EDA2R, EDAR, EGF, EGFR, EPO, EPOR, FAS, FASLG, FLJ78302, FLT1, FLT3, FLT3LG, FLT4, GDF5, GH1, GH2, GHR, HGF, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNAR1, IFNAR2, IFNB1, IFNE1, IFNG, IFNGR1, IFNGR2, IFNK, IFNW1, IL10, IL10RA, IL10RB, IL11, IL11RA, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA1, IL15, IL15RA, IL17A, IL17B, IL17RA, IL17RB, IL18, IL18R1, IL18RAP, IL19, IL1A, IL1B, IL1R1, IL1R2, IL1RAP, IL2, IL20, IL20RA, IL21, IL21R, IL22, IL22RA1, IL22RA2, IL23A, IL23R, IL24, IL25, IL26, IL28A, IL28B, IL28RA, IL29, IL2RA, IL2RB, IL2RG, IL3, IL3RA, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL6ST, IL7, IL7R, IL8, IL8RA, IL8RB, IL9, IL9R, INHBA, INHBB, INHBC, INHBE, KDR, KIT, KITLG, LEP, LEPR, LIF, LIFR, LOC728045, LTA, LTB, LTBR, MET, MPL, NGFR, OSM, OSMR, PDGFB, PDGFC, PDGFRA, PDGFRB, PF4, PF4V1, PLEKHO2, PPBP, PRL, PRLR, RELT, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B, TNFRSF12A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF1A, TNFRSF1B, TNFRSF21, TNFRSF25, TNFRSF4, TNFRSF6B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18, TNFSF4, TNFSF8, TNFSF9, TPO, TSLP, VEGFA, VEGFB, VEGFC, XCL1, XCL2, XCR1 | 242 | ACVR2B(1), CCL11(1), CCL16(1), CCL20(1), CCL21(1), CD70(1), CSF3R(1), EGFR(2), FLT1(1), FLT3(56), IL1R1(1), KDR(2), KIT(9), MPL(1), PDGFRA(1), PDGFRB(1), TPO(1) | 49587855 | 82 | 78 | 52 | 4 | 7 | 5 | 2 | 27 | 40 | 1 | 1.22e-15 | 2.05e-13 |
4 | HSA00271_METHIONINE_METABOLISM | Genes involved in methionine metabolism | AHCY, AMD1, BHMT, CBS, CTH, DNMT1, DNMT3A, DNMT3B, KIAA0828, MARS, MARS2, MAT1A, MAT2B, MTAP, MTFMT, MTR, SRM, TAT | 17 | DNMT1(1), DNMT3A(57), DNMT3B(1), MAT1A(1) | 5703150 | 60 | 53 | 32 | 0 | 36 | 2 | 3 | 5 | 14 | 0 | 1.33e-15 | 2.05e-13 |
5 | NUCLEAR_RECEPTORS | ALK, AR, ESR1, ESR2, ESRRA, HNF4A, NPM1, NR0B1, NR1D2, NR1H2, NR1H3, NR1I2, NR1I3, NR2C2, NR2E1, NR2F1, NR2F2, NR2F6, NR3C1, NR4A1, NR4A2, NR5A1, NR5A2, PGR, PPARA, PPARD, PPARG, RARA, RARB, RARG, ROR1, RORA, RORC, RXRA, RXRB, RXRG, THRA, THRA, NR1D1, THRB, VDR | 38 | NPM1(54), NR2E1(2), THRB(1) | 11589707 | 57 | 56 | 10 | 0 | 1 | 1 | 1 | 1 | 52 | 1 | 2.11e-15 | 2.25e-13 | |
6 | HSA04640_HEMATOPOIETIC_CELL_LINEAGE | Genes involved in hematopoietic cell lineage | ANPEP, CD14, CD19, CD1A, CD1B, CD1C, CD1D, CD1E, CD2, CD22, CD24, CD33, CD34, CD36, CD37, CD38, CD3D, CD3E, CD3G, CD4, CD44, CD5, CD55, CD59, CD7, CD8A, CD8B, CD9, CR1, CR2, CSF1, CSF1R, CSF2, CSF2RA, CSF3, CSF3R, DNTT, EPO, EPOR, FCER2, FCGR1A, FLT3, FLT3LG, GP1BA, GP1BB, GP5, GP9, GYPA, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, IL11, IL11RA, IL1A, IL1B, IL1R1, IL1R2, IL2RA, IL3, IL3RA, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL7, IL7R, IL9R, ITGA1, ITGA2, ITGA2B, ITGA3, ITGA4, ITGA5, ITGA6, ITGAM, ITGB3, KIT, KITLG, MME, MS4A1, TFRC, THPO, TNF, TPO | 83 | CR1(1), CSF3R(1), FLT3(56), HLA-DRB1(1), IL1R1(1), KIT(9), TPO(1) | 23989281 | 70 | 68 | 40 | 1 | 2 | 2 | 1 | 24 | 40 | 1 | 2.44e-15 | 2.25e-13 |
7 | HSA00720_REDUCTIVE_CARBOXYLATE_CYCLE | Genes involved in reductive carboxylate cycle (CO2 fixation) | ACLY, ACO1, ACO2, ACSS1, ACSS2, FH, IDH1, IDH2, LOC441996, MDH1, MDH2, SUCLA2 | 11 | IDH1(19), IDH2(20) | 3866716 | 39 | 38 | 4 | 0 | 33 | 3 | 0 | 3 | 0 | 0 | 2.55e-15 | 2.25e-13 |
8 | METHIONINE_METABOLISM | AHCY, BHMT, CBS, CTH, DNMT1, DNMT2, DNMT3A, DNMT3B, MARS, MARS2, MAT1A, MAT2B, MTR | 12 | DNMT1(1), DNMT3A(57), DNMT3B(1), MAT1A(1) | 4841078 | 60 | 53 | 32 | 0 | 36 | 2 | 3 | 5 | 14 | 0 | 3.11e-15 | 2.39e-13 | |
9 | REDUCTIVE_CARBOXYLATE_CYCLE_CO2_FIXATION | ACO1, ACO2, FH, IDH1, IDH2, MDH1, MDH2, SDHB, SUCLA2 | 9 | IDH1(19), IDH2(20) | 2582079 | 39 | 38 | 4 | 0 | 33 | 3 | 0 | 3 | 0 | 0 | 3.55e-15 | 2.43e-13 | |
10 | KREBPATHWAY | The Krebs (citric acid) cycle takes place in mitochondria, where it extracts energy in the form of electron carriers NADH and FADH2, which drive the electron transport chain. | ACO2, CS, FH, IDH2, MDH1, OGDH, SDHA, SUCLA2 | 8 | IDH2(20) | 2741649 | 20 | 20 | 2 | 0 | 16 | 3 | 0 | 1 | 0 | 0 | 4.66e-15 | 2.47e-13 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | SPRYPATHWAY | Four members of the Sprouty protein family block proliferative EGF signals by binding Grb-2, preventing Ras and MAP kinase activation. | CBL, EGF, EGFR, GRB2, HRAS, MAP2K1, MAPK1, MAPK3, PTPRB, RAF1, RASA1, SHC1, SOS1, SPRY1, SPRY2, SPRY3, SPRY4, SRC | 18 | CBL(2), EGFR(2), MAPK1(1), SHC1(1), SOS1(1) | 7219656 | 7 | 7 | 7 | 2 | 2 | 1 | 1 | 1 | 2 | 0 | 0.0031 | 1 |
2 | ERKPATHWAY | Cell growth is promoted by Ras activation of the anti-apoptotic p44/42 MAP kinase pathway. | DPM2, EGFR, ELK1, GNAS, GNB1, GNGT1, GRB2, HRAS, IGF1R, ITGB1, KLK2, MAP2K1, MAP2K2, MAPK1, MAPK3, MKNK1, MKNK2, MYC, NGFB, NGFR, PDGFRA, PPP2CA, PTPRR, RAF1, RPS6KA1, RPS6KA5, SHC1, SOS1, SRC, STAT3 | 28 | EGFR(2), GNB1(1), MAPK1(1), MYC(1), PDGFRA(1), SHC1(1), SOS1(1) | 9060424 | 8 | 8 | 8 | 1 | 3 | 1 | 0 | 3 | 1 | 0 | 0.0057 | 1 |
3 | EOSINOPHILSPATHWAY | Recruitment of eosinophils in the inflammatory response observed in asthma occurs via the chemoattractant eotaxin binding to the CCR3 receptor. | CCL11, CCL5, CCR3, CSF2, HLA-DRA, HLA-DRB1, IL3, IL5 | 8 | CCL11(1), HLA-DRB1(1) | 893001 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.015 | 1 |
4 | HSA00480_GLUTATHIONE_METABOLISM | Genes involved in glutathione metabolism | ANPEP, G6PD, GCLC, GCLM, GGT1, GGTL3, GGTL4, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, OPLAH, TXNDC12 | 32 | GCLM(1), GPX2(1), GSTK1(2), GSTM3(1) | 5289056 | 5 | 5 | 5 | 0 | 1 | 1 | 0 | 3 | 0 | 0 | 0.017 | 1 |
5 | HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION | Genes involved in neuroactive ligand-receptor interaction | ADCYAP1R1, ADORA1, ADORA2A, ADORA2B, ADORA3, ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, AGTR1, AGTR2, AGTRL1, AVPR1A, AVPR1B, AVPR2, BDKRB1, BDKRB2, BRS3, C3AR1, C5AR1, CALCR, CALCRL, CCKAR, CCKBR, CGA, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CNR1, CNR2, CRHR1, CRHR2, CTSG, CYSLTR1, CYSLTR2, DRD1, DRD2, DRD3, DRD4, DRD5, EDG1, EDG2, EDG3, EDG4, EDG5, EDG6, EDG7, EDG8, EDNRA, EDNRB, F2, F2R, F2RL1, F2RL2, F2RL3, FPR1, FPRL1, FPRL2, FSHB, FSHR, GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GALR1, GALR2, GALR3, GCGR, GH1, GH2, GHR, GHRHR, GHSR, GIPR, GLP1R, GLP2R, GLRA1, GLRA2, GLRA3, GLRB, GNRHR, GPR156, GPR23, GPR35, GPR50, GPR63, GPR83, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, GRM8, GRPR, GZMA, HCRTR1, HCRTR2, HRH1, HRH2, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, KISS1R, LEP, LEPR, LHB, LHCGR, LTB4R, LTB4R2, MAS1, MC1R, MC2R, MC3R, MC4R, MC5R, MCHR1, MCHR2, MLNR, MTNR1A, MTNR1B, NMBR, NMUR1, NMUR2, NPBWR1, NPBWR2, NPFFR1, NPFFR2, NPY1R, NPY2R, NPY5R, NR3C1, NTSR1, NTSR2, OPRD1, OPRK1, OPRL1, OPRM1, OXTR, P2RX1, P2RX2, P2RX3, P2RX4, P2RX5, P2RX7, P2RXL1, P2RY1, P2RY10, P2RY11, P2RY13, P2RY14, P2RY2, P2RY4, P2RY5, P2RY6, P2RY8, PARD3, PPYR1, PRL, PRLHR, PRLR, PRSS1, PRSS2, PRSS3, PTAFR, PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, PTH2R, PTHR1, RXFP1, RXFP2, SCTR, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, TAAR1, TAAR2, TAAR5, TAAR6, TAAR8, TAAR9, TACR1, TACR2, TACR3, TBXA2R, THRA, THRB, TRHR, TRPV1, TSHB, TSHR, TSPO, UTS2R, VIPR1, VIPR2 | 220 | BRS3(1), CTSG(1), DRD2(1), GABBR1(1), GABRA4(1), GABRB1(1), GABRG2(1), GABRR1(1), GLRA1(1), GNRHR(1), GRID1(2), GRIK2(3), GRIK3(1), GRIK4(2), GRM3(2), GRM8(2), HTR5A(1), MCHR2(1), NMUR2(2), NTSR2(1), OPRM1(1), P2RY2(2), PARD3(1), PRSS3(1), SCTR(1), SSTR4(1), THRB(1), VIPR1(1) | 60360209 | 36 | 30 | 36 | 9 | 17 | 7 | 2 | 9 | 1 | 0 | 0.023 | 1 |
6 | ST_G_ALPHA_I_PATHWAY | Gi and Go proteins are members of the same family that transduce cellular signals through both their alpha and beta subunits. | AKT1, AKT2, AKT3, ASAH1, BF, BRAF, DAG1, DRD2, EGFR, EPHB2, GRB2, ITPKA, ITPKB, ITPR1, ITPR2, ITPR3, KCNJ3, KCNJ5, KCNJ9, MAPK1, PI3, PIK3CB, PITX2, PLCB1, PLCB2, PLCB3, PLCB4, RAF1, RAP1GA1, RGS20, SHC1, SOS1, SOS2, SRC, STAT3, TERF2IP | 33 | DAG1(1), DRD2(1), EGFR(2), ITPR1(1), ITPR3(1), MAPK1(1), PIK3CB(1), SHC1(1), SOS1(1) | 16836802 | 10 | 10 | 10 | 4 | 3 | 5 | 0 | 1 | 1 | 0 | 0.025 | 1 |
7 | IL2RBPATHWAY | The beta subunit of the IL-2 receptor is required for IL-2 and IL-15 signal recognition and activates JAK kinase on ligand binding. | AKT1, BAD, BCL2, BCL2L1, CBL, CFLAR, CRKL, E2F1, FOS, GRB2, HRAS, IL2RA, IL2RB, IL2RG, IRS1, JAK1, JAK3, MAPK1, MAPK3, MYC, NMI, PIK3CA, PIK3R1, PPIA, PTPN6, RAF1, RPS6KB1, SHC1, SOCS1, SOCS3, SOS1, STAT5A, STAT5B, SYK, TNFRSF6, TNFSF6, ZNFN1A3 | 33 | CBL(2), JAK3(1), MAPK1(1), MYC(1), SHC1(1), SOS1(1) | 10266655 | 7 | 7 | 7 | 3 | 2 | 2 | 1 | 0 | 2 | 0 | 0.026 | 1 |
8 | CBLPATHWAY | Activated EGF receptors undergo endocytosis into clathrin-coated vesicles, where they are recycled to the membrane or ubiquitinated by Cbl. | CBL, CSF1R, EGF, EGFR, GRB2, MET, PDGFRA, PRKCA, PRKCB1, SH3GLB1, SH3GLB2, SH3KBP1, SRC | 12 | CBL(2), EGFR(2), PDGFRA(1) | 5655476 | 5 | 5 | 5 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0.026 | 1 |
9 | CLASSICPATHWAY | The classic complement pathway is initiated by antibodies and promotes phagocytosis and lysis of foreign cells as well as activating the inflammatory response. | C1QA, C1QB, C1QG, C1R, C1S, C2, C3, C4A, C4B, C5, C6, C7, C8A, C9 | 11 | C2(1), C3(1), C5(1), C7(1) | 5092647 | 4 | 4 | 4 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0.026 | 1 |
10 | ALTERNATIVEPATHWAY | The alternative complement pathway is an antibody-independent mechanism of immune activation that results in cell lysis via the membrane attack complex. | BF, C3, C5, C6, C7, C8A, C9, DF, PFC | 6 | C3(1), C5(1), C7(1) | 3564715 | 3 | 3 | 3 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0.027 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.